Core Financial Performance - The company reported a revenue of $1.05 billion for the first quarter of fiscal year 2026, representing a year-over-year growth of 2.5% [5] - GAAP net profit was $179 million, a decline of 10.9% compared to the previous year [5] - The gross margin decreased to 60.1%, down approximately 150 basis points year-over-year, primarily due to an increase in tariff-related costs of about $15.3 million [4] - Operating cash flow reached $230 million, showing a year-over-year increase of over 20%, indicating strong cash generation capability [4] Business Structure Analysis - The company remains focused on women's health, but performance varies across different segments: - Diagnostic business saw a revenue decline of 1.3% to $464 million, primarily due to a structural decline following the decrease in COVID-19 testing [6][7] - Breast health revenue was $376 million, reflecting a low single-digit growth driven by products related to Endomagnetics [6][7] - Gynecological surgery revenue reached $181 million, growing by 8.7%, supported by acquisitions and product lines like MyoSure and Fluent [6][7] - Skeletal health revenue was $26.7 million, showing a significant growth of 69%, although it remains a small part of the overall structure [6][7] Corporate Background - The company is headquartered in Massachusetts, USA, and is one of the few medical technology companies that focus systematically on women's health [9] - Its core technologies cover a closed-loop strategy of "diagnostics + intervention + surgery" in women's health, which is a key reason for private equity's willingness to invest at high valuations [9] Special Context of Mergers and Acquisitions - The company is currently in a critical phase of being acquired by Blackstone and TPG private equity firms, with a shareholder special meeting scheduled for February 5, 2026, to vote on the merger agreement [1][2] - Due to the ongoing merger process, all public information is primarily based on established facts rather than future operational forecasts or commitments [12] Conclusion - The company maintains stable cash flow from its core women's health business, and the merger process has entered a definitive shareholder voting stage [14]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has entered the IPO inquiry stage on the Sci-Tech Innovation Board, marking it as a representative enterprise in the innovative medical device sector [1][2]. Company Overview - Core Medical was established in 2016 and focuses on the research and industrialization of high-end innovative medical devices, particularly artificial hearts and mechanical circulatory support devices [2][5]. - The company aims to raise 1.217 billion yuan, primarily for the development of cutting-edge products, construction of an artificial heart industrialization base, marketing network, and digital system [2]. Financial Performance - Core Medical has not yet achieved profitability, with revenues of 0 yuan in 2022, 16.55 million yuan in 2023, 93.69 million yuan in 2024, and 70.48 million yuan in the first half of 2025. Corresponding net losses were -178 million yuan, -170 million yuan, -132 million yuan, and -72.75 million yuan [3]. - The company has completed six rounds of financing since its inception, with a valuation of approximately 3.545 billion yuan after the D round in April 2025 and around 3.388 billion yuan during a share transfer in August 2025 [2]. Product Matrix - Core Medical has developed a comprehensive product matrix from implantable to interventional systems, including the Corheart® 6, DuoCor®, and CorVad® series, targeting over 60 million heart failure patients globally [5][9]. - The Corheart® 6, an implantable left ventricular assist device, received NMPA approval in June 2023 and is designed for end-stage heart failure patients [12]. Competitive Landscape - Core Medical's products are positioned against competitors like Abbott's HeartMate 3 and other domestic devices, with a focus on innovative features and clinical data supporting their efficacy [12][13][16][20]. - The company is recognized for its advanced technology in miniaturizing artificial hearts, enhancing its competitiveness in the international market [5][7]. Investment and Financing - In April 2025, Core Medical completed a D round financing exceeding 100 million USD, marking one of the largest market-oriented financings in China's innovative medical device sector that year [10]. - The company has received multiple rounds of institutional investment and is supported by recognized professional institutional investors [10]. Regulatory and Market Considerations - As the inquiry phase begins, Core Medical's market valuation, commercial sustainability, and profitability path are expected to be key areas of regulatory focus, providing important reference points for similar innovative medical device companies [3][22].

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.31%, reaching 24.41 yuan per share, with a trading volume of 597 million yuan and a turnover rate of 4.98%, resulting in a total market capitalization of 15.256 billion yuan [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, provides medical diagnostic services primarily to various healthcare institutions, with its main business revenue composition being 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - Among the top ten circulating shareholders of Dian Diagnostics, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 3.0875 million shares, which is 0.62% of the circulating shares, with an estimated floating profit of approximately 3.7976 million yuan [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 3.677 billion yuan, showing a year-to-date return of 2.54% and a one-year return of 7.87%, but has experienced a loss of 49.97% since its inception [2]

（原标题：港股异动 | 爱康医疗(01789)涨超4% 计划回购最多1.5亿港元股份 26年已有多个关节机器人中 标待公示） 智通财经APP获悉，爱康医疗(01789)涨超4%，截至发稿，涨2.97%，报5.89港元，成交额925.86万港 元。 fund 消息面上，2月2日，爱康医疗发布公告，董事计划使用股份购回授权，并视乎市况，不时于香港联合交 易所有限公司公开市场使用最多1.5亿港元进行建议股份购回，直至股份购回授权届满日期为止。公司 拟以其内部财务资源为建议股份购回提供资金。公司拟于根据适用规则及法规结算后注销所有购回股 份。 值得一提的是，据爱康医疗官微消息，2026年1月15日，爱康医疗旗下子公司壹点灵动申报的注册项目 关节置换手术导航定位系统(国械注准20263010104)已获得NMPA批准的Ⅲ类医疗器械注册证批件，实现 首个全关节手术机器人，覆盖髋、膝、单髁适应症，并可以进行翻修手术。截至目前，公司累计投放市 场近百台关节机器人产品，形成关节机器人与原有假体业务的有效协同，并且2026年已有多个关节机器 人中标待公示，形成了从医工结合到临床应用的闭环落地。 ...

值得一提的是，据爱康医疗官微消息，2026年1月15日，爱康医疗旗下子公司壹点灵动申报的注册项目 关节置换手术导航定位系统(国械注准20263010104)已获得NMPA批准的Ⅲ类医疗器械注册证批件，实现 首个全关节手术机器人，覆盖髋、膝、单髁适应症，并可以进行翻修手术。截至目前，公司累计投放市 场近百台关节机器人产品，形成关节机器人与原有假体业务的有效协同，并且2026年已有多个关节机器 人中标待公示，形成了从医工结合到临床应用的闭环落地。 消息面上，2月2日，爱康医疗发布公告，董事计划使用股份购回授权，并视乎市况，不时于香港联合交 易所有限公司公开市场使用最多1.5亿港元进行建议股份购回，直至股份购回授权届满日期为止。公司 拟以其内部财务资源为建议股份购回提供资金。公司拟于根据适用规则及法规结算后注销所有购回股 份。 爱康医疗(01789)涨超4%，截至发稿，涨2.97%，报5.89港元，成交额925.86万港元。 ...

Group 1 - The core viewpoint of the news is that the healthcare sector, particularly in A-shares and Hong Kong stocks, is experiencing significant activity and investment interest, driven by AI healthcare and CXO concepts [1][5][6] - The largest healthcare ETF in A-shares (512170) saw a net subscription of 2.633 billion yuan over the past 10 days, indicating strong investor interest [1][6] - The Hong Kong healthcare ETF (159137) rose by 2%, ending a three-day decline, with notable performances from stocks like Ark Health and BeiGene, which increased by over 20% and 4% respectively [1][4] Group 2 - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3] - Huawei Cloud launched a dedicated "Smart Healthcare" section aimed at grassroots hospitals, providing AI pathology solutions, in collaboration with Ruijin Hospital [4] - By 2026, AI applications are expected to evolve from usable to highly effective, with a focus on diversified business models in sectors like healthcare, finance, and education [5]

Core Viewpoint - The healthcare sector in A-shares is experiencing a significant rally, driven by AI healthcare and CXO concepts, with notable inflows into medical ETFs [1][8]. Group 1: ETF Performance - The largest medical ETF in A-shares (512170) saw an intraday increase of over 1%, recovering its annual line, with a net subscription of 2.633 billion yuan over the past 10 days as of February 2 [1][8]. - The medical ETF fund size reached 27 billion yuan, making it the largest in the market for medical ETFs [6][13]. Group 2: Individual Stock Movements - The Hong Kong medical ETF (159137) surged by 2%, ending a three-day decline, with Ark Health rising over 20% and BeiGene increasing by more than 4% [10]. - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3][10]. Group 3: Industry Developments - Huawei Cloud launched the first section of its industry AI "Dream Factory" focused on smart healthcare, providing a collaborative pathology solution for grassroots hospitals [5][12]. - Institutions predict that by 2026, AI applications will transition from usable to highly effective, becoming a core theme in the AI industry, particularly in healthcare, finance, and education sectors [6][12].

上市当日，亚辉龙开盘报65.00元，盘中最高报73.80元，为上市以来最高点，收报64.00元。 中国经济网北京2月3日讯亚辉龙(688575.SH)近日发布的2025年度业绩预告显示，预计2025年度实现归 属于母公司所有者的净利润为2,000.00万元至3,000.00万元，与上年同期相比，将减少27,153.36万元至 28,153.36万元，同比减少90.05%至93.37%；预计2025年度实现归属于母公司所有者的扣除非经常性损 益的净利润6,500.00万元至8,500.00万元，与上年同期相比，将减少20,233.33万元至22,233.33万元，同比 减少70.42%至77.38%。 2022年至2024年，亚辉龙的营业收入分别为39.81亿元、20.53亿元和20.12亿元；归属于上市公司股东的 净利润分别为10.12亿元、3.55亿元和3.02亿元；归属于上市公司股东的扣非净利润分别为9.55亿元、 2.20亿元和2.87亿元；经营活动产生的现金流量净额分别为15.83亿元、-7318.76万元和5.30亿元。 亚辉龙募集资金总额为60,680.00万元，募集资金净额为54,133.44万 ...

资料显示，青岛海尔生物医疗股份有限公司位于山东省青岛市高新区丰源路280号海尔生物医疗新兴产 业园，成立日期2005年10月28日，上市日期2019年10月25日，公司主营业务涉及生物医疗低温存储设备 的研发、生产和销售。主营业务收入构成为：医疗器械及相关产品98.81%，安装收入0.74%，软件维护 服务收入0.42%，租赁收入0.02%。 截至1月20日，海尔生物股东户数1.40万，较上期增加5.33%；人均流通股22571股，较上期减少5.06%。 2025年1月-9月，海尔生物实现营业收入17.61亿元，同比减少1.17%；归母净利润1.98亿元，同比减少 35.83%。 2月2日，海尔生物跌3.42%，成交额1.13亿元。两融数据显示，当日海尔生物获融资买入额1721.44万 元，融资偿还2360.88万元，融资净买入-639.44万元。截至2月2日，海尔生物融资融券余额合计2.47亿 元。 融资方面，海尔生物当日融资买入1721.44万元。当前融资余额2.45亿元，占流通市值的2.41%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，海尔生物2月2日融券偿还2300.00股，融券卖出 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical has experienced fluctuations in its stock performance and financing activities, indicating a mixed market sentiment towards the company [1][2]. - On February 2, Xinmai Medical's stock fell by 2.87%, with a trading volume of 154 million yuan, and a net financing purchase of 9 million yuan, suggesting a cautious investor approach [1]. - As of February 2, the total balance of margin trading for Xinmai Medical was 482 million yuan, with a financing balance of 479 million yuan, representing 4.21% of its market capitalization, which is below the 20th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for Xinmai Medical decreased by 8.73% to 16,000, while the average circulating shares per person increased by 9.56% to 7,708 shares [2]. - For the period from January to September 2025, Xinmai Medical reported a revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, but the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The company has distributed a total of 1.079 billion yuan in dividends since its A-share listing, with 817 million yuan distributed over the past three years [2].